Pelthos Therapeutics Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$33
Valuation models combined (2)
Base case. Range ~$30–$47. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Pelthos Therapeutics Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 29% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
We value Pelthos Therapeutics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.19 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$30 | Primary model, counts double |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: book value or earnings not available |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$47 ~$39–$110 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$33 ~$30–$47 | 2 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Pelthos Therapeutics Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2024 | 2025 |
|---|---|---|
| Share price | $6.41 | $31.00 |
| Market value | $4m | $58m |
| + Net debt (− = net cash) | −$513000 | $13m |
| Enterprise value | $3m | $72m |
| Multiples | ||
| Price / sales | — | 3.5x |
| Price / earnings | — | — |
| Price / free cash flow | — | — |
| EV / EBITDA | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Next results: November 12, 2026, before the open. Analysts expect revenue of $17m and EPS of −$3.33 (range −$4.60 to −$1.60) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$18.02 | −36% | $62m | +271% |
| Next | −$5.37 | +70% | $108m | +74% |
The consensus EPS forecast for the current fiscal year is +69.0% on 90 days ago. In the last 30 days, 0 analysts raised Pelthos Therapeutics Inc.'s forecast and 2 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$10.66 | −$2.13 |
| 60 days ago | −$18.82 | −$5.68 |
| 30 days ago | −$18.82 | −$5.68 |
| 7 days ago | −$17.87 | −$5.14 |
| Now | −$18.02 | −$5.37 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$2.95 | −$3.79 | −28.6% |
| Mar 2026 | −$3.58 | −$4.66 | −30.2% |
| Dec 2025 | −$4.18 | −$2.69 | +35.8% |
| Sept 2025 | −$0.57 | −$5.30 | −821.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2025 | 2026 to date |
|---|---|---|
| Return | ||
| PTHS | +384% | −63% |
| Industry peers (median) | +7% | −12% |
| S&P 500 | +18% | +11% |
| Months that ended higher | ||
| PTHS | 58% | 55% |
| S&P 500 | 75% | 46% |
| Largest fall from a high during the year | ||
| PTHS | −67% | −70% |
| S&P 500 | −19% | −9% |
Worst fall since February 16, 2024: 89% from February 16, 2024 to November 19, 2024. Getting back needed a 787% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 13, 2026 | −4.9% | +0.5% | −7.8% | −24.1% |
| May 14, 2026 | +2.7% | −0.4% | +4.2% | +1.9% |
| March 19, 2026 | −13.9% | −1.7% | −5.6% | −4.7% |
| November 13, 2025 | −10.1% | −1.7% | −22.5% | −40.5% |
| August 18, 2025 | −2.1% | −0.6% | +7.8% | +56.0% |
| Fiscal year | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|
| Income | |||
| Revenue | 0 | 17 | 43 |
| Gross profit | 0 | 13 | 34 |
| EBITDA | −8 | −32 | −56 |
| Operating income | −8 | −32 | −58 |
| Net income | −8 | −43 | −86 |
| Diluted EPS | −$14.27 | −$23.04 | — |
| Margins | |||
| Gross margin | — | 76.3% | 78.6% |
| EBITDA margin | — | −188.8% | −130.0% |
| Operating margin | — | −193.1% | −133.4% |
| Net margin | — | −257.9% | −199.5% |
| Free-cash-flow margin | — | −135.1% | — |
| Cash flow | |||
| Cash from operations | −6 | −23 | −42 |
| Capital spending | 0 | 0 | — |
| Free cash flow | −6 | −23 | — |
| Stock-based pay | 2 | 5 | 8 |
| Free cash flow after stock pay | −8 | −28 | — |
| Balance sheet | |||
| Cash | 1 | 18 | 24 |
| Total debt | 0 | 31 | 43 |
| Net debt (negative = net cash) | −1 | 13 | 19 |
| Diluted shares | — | 2m | — |
| Returned to shareholders | |||
| Buybacks | 0 | 0 | — |
| Total returned | 0 | 0 | — |
| Quarter | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|
| Income | ||||||
| Revenue | 0 | 0 | 7 | 9 | 11 | 16 |
| Gross profit | 0 | 0 | 5 | 8 | 9 | 12 |
| EBITDA | −2 | −3 | −15 | −12 | −13 | −17 |
| Operating income | −2 | −3 | −15 | −12 | −13 | −17 |
| Net income | −2 | −3 | −16 | −22 | −25 | −23 |
| Diluted EPS | −$3.21 | −$5.29 | −$5.30 | −$8.08 | −$7.57 | −$6.62 |
| Margins | ||||||
| Gross margin | — | — | 68.7% | 82.2% | 84.7% | 76.9% |
| EBITDA margin | — | — | −202.2% | −124.2% | −115.7% | −109.2% |
| Operating margin | — | — | −207.4% | −127.8% | −120.0% | −111.0% |
| Net margin | — | — | −219.3% | −230.7% | −229.9% | −150.1% |
| Free-cash-flow margin | — | — | — | — | −122.1% | −49.1% |
| Cash flow | ||||||
| Cash from operations | −1 | −0 | −15 | −6 | −13 | −8 |
| Capital spending | 0 | 0 | — | — | 0 | 0 |
| Free cash flow | −1 | −0 | — | — | −13 | −8 |
| Stock-based pay | 0 | 0 | 2 | 2 | 2 | 3 |
| Free cash flow after stock pay | −1 | −1 | — | — | −15 | −10 |
| Last 12 months unless stated | PTHS | BFRI | CPIX | IMCC | BGM | SBFM | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $43m | $46m | $40m | $39m | $38m | $35m | $254m |
| Revenue growth, last 12 months | — | 17.8% | −5.2% | −0.7% | 51.1% | −2.7% | 9.9% |
| Revenue growth, 3-year average | — | 16.7% | −0.6% | — | — | 34.5% | 5.5% |
| Revenue growth, latest quarter | — | 32.9% | −18.8% | — | — | −1.6% | 6.5% |
| Gross margin | 78.6% | — | 82.9% | 17.7% | 16.6% | 30.3% | 63.8% |
| Operating margin | −133.4% | −14.2% | −24.1% | −21.2% | −33.2% | −16.6% | −5.9% |
| Operating margin, 3-year average | — | −36.6% | −19.0% | — | — | −16.5% | −7.4% |
| Net margin | −199.5% | −13.8% | −27.4% | −20.7% | −52.6% | −16.5% | −7.4% |
| Cash from operations / revenue | −97.7% | −17.2% | 1.9% | 8.6% | −6.3% | −15.1% | 9.4% |
| Free-cash-flow margin | −101.1% | −17.2% | 1.7% | 8.6% | −10.4% | −15.2% | 8.1% |
| Free-cash-flow margin, 3-year average | — | −31.6% | 5.4% | — | — | −25.5% | 7.4% |
| Stock pay / revenue | 19.6% | 2.4% | 1.1% | 0.0% | 27.0% | — | 3.7% |
| Change in share count | — | — | 1.5% | 71.3% | >999% | 55.7% | 1.9% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Commercial Operations | $16.2M | 96.5% | — |
| Research and Development Operations | $589,000 | 3.5% | — |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Net Product | $16.2M | 96.5% | — |
| License and Collaboration | $589,000 | 3.5% | — |
From Pelthos Therapeutics Inc.'s 10-K filed March 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Aigh Capital Management LLC | $9.3M | 329K | 24.2% | New |
| Murchinson Ltd. | $8.6M | 304K | 22.4% | ▲ 2.7% |
| Ikarian Capital, LLC | $7.3M | 257K | 18.8% | 0.0% |
| Boothbay Fund Management, LLC | $2.9M | 102K | 7.5% | ▲ 24.6% |
| Vanguard Capital Management LLC | $2.7M | 97K | 7.1% | ▲ 4.3% |
| Cantor Fitzgerald, L. P. | $2.2M | 76K | 5.6% | ▲ 84.1% |
| J. Goldman & Co LP | $1.1M | 38K | 2.8% | ▼ 24.5% |
| Diadema Partners LP | $700,085 | 25K | 1.8% | 0.0% |
| Wexford Capital LP | $632,007 | 22K | 1.6% | New |
| Knott David M Jr | $623,783 | 22K | 1.6% | ▲ 4.7% |
| Citadel Advisors LLC | $425,200 | 15K | 1.1% | New |
| Geode Capital Management, LLC | $414,008 | 15K | 1.1% | ▼ 4.2% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Pelthos Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Pauls Matthew Director | October 2, 2026 | Sell pre-set plan | 786 | $21.00 | $16,506 |
| Friedberg Ezra M Director | October 2, 2026 | Sell pre-set plan | 558 | $20.72 | $11,560 |
| Greenleaf Peter Director | October 2, 2026 | Sell pre-set plan | 797 | $21.17 | $16,872 |
| Greenleaf Peter Director | July 2, 2026 | Sell pre-set plan | 85 | $27.27 | $2,318 |
| Greenleaf Peter Director | July 2, 2026 | Sell pre-set plan | 712 | $26.00 | $18,512 |
| Pauls Matthew Director | July 2, 2026 | Sell pre-set plan | 692 | $26.00 | $17,992 |
| Pauls Matthew Director | July 2, 2026 | Sell pre-set plan | 94 | $27.36 | $2,572 |
| Friedberg Ezra M Director | July 2, 2026 | Sell pre-set plan | 24 | $27.33 | $656 |
| Friedberg Ezra M Director | July 2, 2026 | Sell pre-set plan | 534 | $26.03 | $13,900 |
| Friedberg Ezra M Director | June 15, 2026 | Sell pre-set plan | 59 | $27.94 | $1,648 |
| Friedberg Ezra M Director | June 15, 2026 | Sell pre-set plan | 224 | $27.12 | $6,075 |
| Davis Todd C Director | June 11, 2026 | Buy | 35,445 | $27.80 | $985,371 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
